We assessed the sedative potential of continuous infusions of remifentanil
with a validated composite alertness scale in 160 patients (ASA physical st
atus I or Il) undergoing hip replacement surgery with spinal block (n = 61)
or hand surgery using brachial plexus block (n = 93). They were randomized
to receive one of the following initial dose regimens in double-blinded fa
shion: placebo or 0.04, 0.07, or 0.1 mu g.kg(-1).min(-1) remifentanil subse
quently titrated to effect. Additional midazolam IV was allowed for adequat
e sedation as required. The combined analysis of both surgery groups reveal
ed a dose-related increase in achievement of sedation level greater than or
equal to 2 within 15 min of the start of the study drug infusion; all remi
fentanil dose comparisons with placebo reached significance (P < 0.001). Th
e remifentanil 50% effective dose for a composite sedation level greater th
an or equal to 2 within 15 min of the start of drug infusion was estimated
as 0.043 mu g.kg(-1).min(-1) (95% confidence interval 0.01, 0.059). The req
uirement for midazolam decreased with increasing remifentanil dose compared
with placebo (P < 0.001). The median time to return to alertness after the
end of infusion was 10-12 min in the remifentanil groups and 5 min in the
placebo group. Significant incidences of nausea, pruritus, sweating, and re
spiratory depression were reported during remifentanil infusions compared w
ith placebo. The data suggest that remifentanil may be useful for supplemen
tation of regional anesthesia, provided that ventilation is carefully monit
ored. Implications: In this dose-finding, placebo-controlled study, remifen
tanil infusions were used to provide sedation during spinal and brachial pl
exus regional anesthesia. The 50% effective dose for achievement of sedatio
n was 0.043 mu g.kg(-1).min(-1). Return to alertness occurred after 10-12 m
in (median time). Remifentanil infusions can be used to supplement regional
anesthesia, but this requires careful monitoring of ventilation.